Nothing Special   »   [go: up one dir, main page]

WO2003049692A3 - The use of acyl salicylates as heat shock inducers - Google Patents

The use of acyl salicylates as heat shock inducers Download PDF

Info

Publication number
WO2003049692A3
WO2003049692A3 PCT/US2002/039150 US0239150W WO03049692A3 WO 2003049692 A3 WO2003049692 A3 WO 2003049692A3 US 0239150 W US0239150 W US 0239150W WO 03049692 A3 WO03049692 A3 WO 03049692A3
Authority
WO
WIPO (PCT)
Prior art keywords
inducers
heat shock
salicylates
acyl
acyl salicylates
Prior art date
Application number
PCT/US2002/039150
Other languages
French (fr)
Other versions
WO2003049692A2 (en
Inventor
George Cioca
Mose Rossi
Rosa Mario De
Original Assignee
George Cioca
Estee Lauder Inc
Mose Rossi
Rosa Mario De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Cioca, Estee Lauder Inc, Mose Rossi, Rosa Mario De filed Critical George Cioca
Priority to JP2003550743A priority Critical patent/JP2005513045A/en
Priority to EP02794193A priority patent/EP1456353A4/en
Priority to CA002469143A priority patent/CA2469143A1/en
Priority to AU2002359641A priority patent/AU2002359641A1/en
Priority to US10/496,470 priority patent/US20060148767A1/en
Publication of WO2003049692A2 publication Critical patent/WO2003049692A2/en
Publication of WO2003049692A3 publication Critical patent/WO2003049692A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Magnetic Ceramics (AREA)

Abstract

The invention relates to acyl-salicylates as heat shock response inducers and the use thereof as active ingredients in cosmetic and/or pharmaceutical preparations.
PCT/US2002/039150 2001-12-06 2002-12-06 The use of acyl salicylates as heat shock inducers WO2003049692A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2003550743A JP2005513045A (en) 2001-12-06 2002-12-06 Use of acyl salicylates as heat shock inducers.
EP02794193A EP1456353A4 (en) 2001-12-06 2002-12-06 The use of acyl salicylates as heat shock inducers
CA002469143A CA2469143A1 (en) 2001-12-06 2002-12-06 The use of acyl salicylates as heat shock inducers
AU2002359641A AU2002359641A1 (en) 2001-12-06 2002-12-06 The use of acyl salicylates as heat shock inducers
US10/496,470 US20060148767A1 (en) 2001-12-06 2002-12-06 Use of acyl salicylates as heat shock inducers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI002573A ITMI20012573A1 (en) 2001-12-06 2001-12-06 ACYLSALICYLATES: A NEW CLASS OF HEAT SHOCK RESPONSE INDUCTORS
ITMI2001A002573 2001-12-06

Publications (2)

Publication Number Publication Date
WO2003049692A2 WO2003049692A2 (en) 2003-06-19
WO2003049692A3 true WO2003049692A3 (en) 2003-12-04

Family

ID=11448668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039150 WO2003049692A2 (en) 2001-12-06 2002-12-06 The use of acyl salicylates as heat shock inducers

Country Status (6)

Country Link
EP (1) EP1456353A4 (en)
JP (1) JP2005513045A (en)
AU (1) AU2002359641A1 (en)
CA (1) CA2469143A1 (en)
IT (1) ITMI20012573A1 (en)
WO (1) WO2003049692A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
PT2659904E (en) 2008-06-26 2016-01-22 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
KR20240028540A (en) 2014-09-15 2024-03-05 제브라 덴마크 에이/에스 Arimoclomol formulation
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
RU2750154C2 (en) 2016-04-29 2021-06-22 Орфазим А/С Arimoclomol for treatment of glucocerebrosidase-associated disorders
MX2023005954A (en) 2020-11-19 2023-09-04 Zevra Denmark As Processes for preparing arimoclomol citrate and intermediates thereof.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917088A (en) * 1997-04-30 1999-06-29 L'oreal Salicyclic acid derivatives, process of preparation and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU87408A1 (en) * 1988-12-16 1990-07-10 Oreal USE OF SALICYL DERIVATIVES FOR THE TREATMENT OF AGING SKIN
US5760261A (en) * 1990-02-28 1998-06-02 Guttag; Alvin Higher fatty acid derivatives of salicylic acid and salts thereof
US5599959A (en) * 1995-01-31 1997-02-04 University Of Maryland Analogues of acetylsalicylic acid and novel uses thereof
AUPO612397A0 (en) * 1997-04-11 1997-05-08 University Of Queensland, The Novel diflunisal esters and related compounds
CN1939895B (en) * 2000-04-19 2010-05-12 纽若泰克有限公司 Compound, composition and method for preventing from neurodegeneration in injury of central nervous system
FR2808999B1 (en) * 2000-05-19 2002-11-01 Oreal COSMETIC COMPOSITION IN POWDER FORM COMPRISING A PARTICULAR BINDER

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917088A (en) * 1997-04-30 1999-06-29 L'oreal Salicyclic acid derivatives, process of preparation and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1456353A4 *

Also Published As

Publication number Publication date
AU2002359641A1 (en) 2003-06-23
WO2003049692A2 (en) 2003-06-19
JP2005513045A (en) 2005-05-12
EP1456353A4 (en) 2006-05-31
ITMI20012573A1 (en) 2003-06-06
EP1456353A2 (en) 2004-09-15
CA2469143A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
HUP0402497A3 (en) Pharmaceutical compositions containing two activ ingredients and their uses
WO2002085299A3 (en) Therapeutic treatments using the direct application of antimicrobial metal compositions
IL193234A0 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
HUP0400240A3 (en) Combinations of substituted oxazolidinones and other active ingredients and pharmaceutical compositions containing them
EP1426027A4 (en) Composition and cosmetic preparation containing the same
BR0112962B1 (en) Pharmaceutical compositions comprising hyaluronic acid, glycyrretinic acid and polyvinylpyrrolidone, and their use in the preparation of medicaments.
AU2002342907A1 (en) Gel capsules containing active ingredients and use thereof
HUP9903216A3 (en) Substituted benzamide and use of them as active ingredient in pharmaceutical compositions
HUP0400119A3 (en) Pharmaceutical and/or cosmetic compositions for the treatment of localised adiposities and cellulite
PL366855A1 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
WO2001034641A3 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
NO20035581D0 (en) Pharmaceutical formulation with masked taste and preparation thereof
WO2001045650A3 (en) Cosmetic use of the residues from wine production
WO2003049692A3 (en) The use of acyl salicylates as heat shock inducers
EP1370241A4 (en) Multi-lamellar emulsion(mle) for stabilizing dermatologically useful ingredients and external base preparations for general skin diseases utilizing the same
IL160474A0 (en) Combination products of 1,4-benzothiepine 1,1-dioxide derivatives with other active ingredients and the use thereof
AU2001282730A1 (en) Seal-oil-based pharmaceutical, cosmetic, dermo-cosmetic, hygiene, alimentary andpara-alimentary (food-supplements) products; their methods of preparation; thei r uses as preventive and/or as therapeutic agents
IL152202A0 (en) Human kcnq5 polypeptide and pharmaceutical compositions containing the same
FR2810540B1 (en) NEW COSMETIC OR HYGIENIC PREPARATIONS IN THE FORM OF DISPERSION
WO2003037288A3 (en) Cosmetic composition that mimics sebum and the use thereof
AU2002343042A8 (en) Virulence proteins of the genus yersinia and uses thereof
IL158860A0 (en) Nucleic acids and corresponding proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer and pharmaceutical compositions containing the same
WO2002077233A8 (en) 38650, 28472, 5495, 65507, 81588 and 14354 METHODS AND COMPOSITIONS OF HUMAN PROTEINS AND USES THEREOF
AU8387601A (en) Novel pharmaceutical composition for the topical application of water-insoluble and/or hardly water-soluble active agents
AR026890A1 (en) COMPOSITIONS OF TENOCITS, PREPARATIONS AND USES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002359641

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2469143

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003550743

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002794193

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002794193

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006148767

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10496470

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10496470

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002794193

Country of ref document: EP